BTIG Maintains Buy on Bionano Genomics, Lowers Price Target to $2
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Mark Massaro maintains a Buy rating on Bionano Genomics (NASDAQ:BNGO) but lowers the price target from $3 to $2.
May 16, 2024 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
BTIG analyst Mark Massaro maintains a Buy rating on Bionano Genomics but lowers the price target from $3 to $2.
The Buy rating suggests continued confidence in the company's long-term prospects, but the lowered price target indicates a more cautious short-term outlook. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100